188 related articles for article (PubMed ID: 29562907)
1. Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients.
Bo X; Wang J; Suo T; Ni X; Liu H; Shen S; Li M; Wang Y; Liu H; Xu J
BMC Cancer; 2018 Mar; 18(1):313. PubMed ID: 29562907
[TBL] [Abstract][Full Text] [Related]
2. High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer.
Bo X; Wang J; Wang C; Nan L; Gao Z; Xin Y; Li M; Shen S; Liu H; Ni X; Suo T; Zhang D; Lu P; Wang Y; Liu H
Cancer Sci; 2020 Mar; 111(3):817-825. PubMed ID: 31925976
[TBL] [Abstract][Full Text] [Related]
3. Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma.
Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Wang Z; Xie H; Dai B; Xu J; Ye D
Ann Surg Oncol; 2017 May; 24(5):1435-1442. PubMed ID: 27896514
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
[TBL] [Abstract][Full Text] [Related]
5. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
Kainuma O; Miura F; Furukawa D; Yamamoto H; Cho A; Sano K; Nakagohri T; Asano T
J Hepatobiliary Pancreat Sci; 2015 Nov; 22(11):789-94. PubMed ID: 26234468
[TBL] [Abstract][Full Text] [Related]
8. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
[TBL] [Abstract][Full Text] [Related]
9. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
10. Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom.
Huggett MT; Passant H; Hurt C; Pereira SP; Bridgewater J; Mukherjee S
Tumori; 2014; 100(2):219-24. PubMed ID: 24852869
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
Suzuki Y; Kan M; Kimura G; Umemoto K; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Imaoka H; Ohno I; Mitsunaga S; Ikeda M
J Gastroenterol; 2019 Mar; 54(3):281-290. PubMed ID: 30298469
[TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 in advanced biliary tract cancer patients treated with chemotherapy: prognostic and predictive roles.
da Costa Miranda V; Braghiroli MI; Faria LD; Siqueira SA; Sabbaga J; Hoff PM; Riechelmann RP
J Gastrointest Cancer; 2014 Mar; 45(1):80-6. PubMed ID: 24326865
[TBL] [Abstract][Full Text] [Related]
14. Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
Lamarca A; Edeline J; McNamara MG; Hubner RA; Nagino M; Bridgewater J; Primrose J; Valle JW
Cancer Treat Rev; 2020 Mar; 84():101936. PubMed ID: 31986437
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO).
Unal OU; Oztop I; Kos T; Assoc ; Turan N; Kucukoner M; Helvaci K; Berk V; Sevinc A; Yildiz R; Cinkir Hy; Tonyali O; Demirci U; Aktas B; Balakan O; Yilmaz AU
Asian Pac J Cancer Prev; 2014; 15(22):9687-92. PubMed ID: 25520089
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
Lamarca A; Benafif S; Ross P; Bridgewater J; Valle JW
Eur J Cancer; 2015 Sep; 51(13):1694-703. PubMed ID: 26066735
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.
Moehler M; Maderer A; Ehrlich A; Foerster F; Schad A; Nickolay T; Ruckes C; Weinmann A; Sivanathan V; Marquardt JU; Galle PR; Woerns M; Thomaidis T
BMC Cancer; 2019 Jan; 19(1):55. PubMed ID: 30634942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
